Moody's Ratings (Moody's) upgraded Insulet Corporation's ("Insulet") corporate family rating ("CFR") to Ba2 from Ba3 and Probability of Default Rating ("PDR") to Ba2-PD from Ba3-PD. Concurrently, we upgraded the ratings on Insulet's senior secured term loan and senior secured revolving credit facili...
We consider the merged platform Kadimastem (KDST.TA) + NLS Pharmaceutics (NLSP:NasdaqCM). We provide an investment case analysis and a selection of merged metrics prior to any synergies. The merger creates a cross-platform pre-revenue biotech with lead programs including a proprietary stem-differentiation platform capable of delivering scalable therapies for replacing lost or damaged cells; IsletRx could revolutionize insulin production for Type 1 diabetes (T1D) patients; AstroRx® targets neurod...
Moody's Ratings (Moody's) upgraded Insulet Corporation's ("Insulet") Corporate Family Rating (CFR) to Ba3 from B1 and Probability of Default Rating ("PDR") to Ba3-PD from B1-PD. Concurrently, we affirmed the Ba2 rating on Insulet's senior secured term loan and assigned a Ba2 rating to Insulet's new ...
Diabetes mellitus, Type 1 (T1D) and Type 2 (T2D, 85-90% of cases), is a USD ~75bn global therapy market. Global economic costs of diabetes may exceed USD1 trn today and USD 450bn in the US, suggesting a pressing global health challenge. Diabetes is a chronic metabolic disorder characterized by high blood sugar levels. In 2024, consensus global estimates suggested there were ~800m adult diabetes sufferers. In 2021, according to the IDF there >530m sufferers globally. For 2027E we modestly forecas...
Moody's Ratings (Moody's) upgraded Insulet Corporation's ("Insulet") Corporate Family Rating (CFR) to B1 from B2 and Probability of Default Rating ("PDR") to B1-PD from B2-PD. Concurrently, we affirmed the Ba2 ratings on Insulet's senior secured credit facilities, including the senior secured term l...
Moody's Investors Service ("Moody's") affirmed the ratings of Insulet Corporation, ("Insulet") including the Corporate Family Rating ("CFR") at B2, and Probability of Default Rating ("PDR") at B2-PD. At the same time, Moody's upgraded Insulet's ratings on the senior secured term loan and senior secu...
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
The general evaluation of INSULET (US), a company active in the Medical Equipment industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 4 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date February 15, 2022, the closing price was USD...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.